Veronica Bunn

Takeda (United States) — United States

Medicine · Health Sciences

15h-index1.4kcitations54works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(26), Lymphoma Diagnosis and Treatment(14), Colorectal Cancer Treatments and Studies(12), CAR-T cell therapy research(11), PI3K/AKT/mTOR signaling in cancer(10)

Publications54 total

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity
Nature Communications·2025· 2 citedOpen Access
Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level data
Journal of Biopharmaceutical Statistics·2024· 1 cited
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing
Statistics in Biopharmaceutical Research·2023· 3 cited
586P Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Annals of Oncology·2023· 1 cited
1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Annals of Oncology·2023· 2 citedOpen Access
Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
2023Open Access
Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
2023Open Access
Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
2023Open Access
Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
2023Open Access
Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
2023Open Access
Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
2023Open Access
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study
Lung Cancer·2023
Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol
Therapeutic Innovation & Regulatory Science·2023· 8 cited
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion–positive non–small cell lung cancer
Figshare·2023Open Access
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion–positive non–small cell lung cancer
Expert Review of Anticancer Therapy·2022· 9 cited
Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses
Journal of Biopharmaceutical Statistics·2022· 8 cited
Mobocertinib (TAK-788) in <i>EGFR</i> exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.
Journal of Clinical Oncology·2022· 7 cited
Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with <i>EGFR </i>exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib.
Journal of Clinical Oncology·2022· 3 cited
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
Blood Advances·2022· 39 citedOpen Access
Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study
Lung Cancer·2022
page 1 of 3Next →

Frequent Co-authors

Jianchang Lin(28), Pasi A. Jänne(19), Gregory J. Riely(18), Tarek Mekhail(17), Shu Jin(17), Danny Nguyen(16), Sylvie Vincent(14), Pier Luigi Zinzani(13), Alexander I. Spira(13), Zofia Piotrowska(13), Suresh S. Ramalingam(11), Enriqueta Felip(10), Minal Mehta(10), Sarah McCue Horwitz(10), James Chih‐Hsin Yang(9), M.R. García Campelo(8), Owen A. O’Connor(8), Barbara Pro(8), Swaminathan P. Iyer(8), Ranjana H. Advani(8)